TriangleNCT00963911 · OUTCOME
Sensitivity of the VES-13 Questionnaire
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- % of Participants with a positive VES13
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- at inclusion
What was measured
Sensitivity of the VES-13 questionnaire measured as percentage of participants with a positive VES-13 test among patients with a positive MGA. VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For 3 pre-identified centers, patients filled in the questionnaire at the following geriatric visit. VES-13 consisted of 4 groups of questions: age, self-perceived health, difficulties to perform 6 specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score \>=3 was considered to show impairment. Multidimensional geriatric assessment (MGA): see measure description for primary outcome.
Analysis population: Eligible Patients Assessable for the Primary Outcome Measure AND with a positive VES-13
Groups in this outcome
Eligible Patients Assessable for the Primary Outcome Measure
Patients older than 70 years and included either before any first-line treatment, or between any two steps of a pre-defined first-line treatment sequence (chemotherapy, endocrine therapy, targeted treatment, surgery or radiotherapy) for various types of histologically-confirmed cancer (colon, lung, upper aero digestive tract (UAT)/head and neck, breast, prostate, and non-Hodgkin's lymphomas (NHL)), and for whom G8 as well as at least one instrument of the multidimensional assessment were available.
| Group | Source count |
|---|---|
| Eligible Patients Assessable for the Primary Outcome Measure | 1151 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Eligible Patients Assessable for the Primary Outcome Measure | 68.7 | Not reported | 66.0 | 71.4 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 66.0
- upper Limit
- 71.4
- value
- 68.7
- denoms
- counts
- group Id
- OG000
- value
- 1151
- units
- Participants
- description
- Sensitivity of the VES-13 questionnaire measured as percentage of participants with a positive VES-13 test among patients with a positive MGA. VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For 3 pre-identified centers, patients filled in the questionnaire at the following geriatric visit. VES-13 consisted of 4 groups of questions: age, self-perceived health, difficulties to perform 6 specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score \>=3 was considered to show impairment. Multidimensional geriatric assessment (MGA): see measure description for primary outcome.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients older than 70 years and included either before any first-line treatment, or between any two steps of a pre-defined first-line treatment sequence (chemotherapy, endocrine therapy, targeted treatment, surgery or radiotherapy) for various types of histologically-confirmed cancer (colon, lung, upper aero digestive tract (UAT)/head and neck, breast, prostate, and non-Hodgkin's lymphomas (NHL)), and for whom G8 as well as at least one instrument of the multidimensional assessment were available.
- id
- OG000
- title
- Eligible Patients Assessable for the Primary Outcome Measure
- param Type
- NUMBER
- population Description
- Eligible Patients Assessable for the Primary Outcome Measure AND with a positive VES-13
- reporting Status
- POSTED
- time Frame
- at inclusion
- title
- Sensitivity of the VES-13 Questionnaire
- type
- SECONDARY
- unit Of Measure
- % of Participants with a positive VES13
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice